Literature DB >> 4334086

Clinical trials with the antitumor agent 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide(NSC-45388).

J K Luce, W G Thurman, B L Isaacs, R W Talley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4334086

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


× No keyword cloud information.
  7 in total

Review 1.  State of melanoma: an historic overview of a field in transition.

Authors:  Vikram C Gorantla; John M Kirkwood
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

Review 2.  Translating Molecules into Imaging-The Development of New PET Tracers for Patients with Melanoma.

Authors:  Laetitia Vercellino; Dorine de Jong; Laurent Dercle; Benoit Hosten; Brian Braumuller; Jeeban Paul Das; Aileen Deng; Antoine Moya-Plana; Camry A'Keen; Randy Yeh; Pascal Merlet; Barouyr Baroudjian; Mary M Salvatore; Kathleen M Capaccione
Journal:  Diagnostics (Basel)       Date:  2022-04-29

3.  Clinical pharmacokinetics of high-dose DTIC.

Authors:  J M Buesa; E Urréchaga
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 4.  N-methyl antitumour agents. A distinct class of anticancer drugs?

Authors:  D Newell; A Gescher; S Harland; D Ross; C Rutty
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

5.  A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors.

Authors:  D R Adkins; R Irvin; J Kuhn; D H Boldt; G D Roodman; D Salzman; C Freytes; D D Von Hoff; C F LeMaistre
Journal:  Invest New Drugs       Date:  1993 May-Aug       Impact factor: 3.850

6.  Chemotherapy of malignant melanoma with dimethyl traizeno imidazole carboxamide (DITC) and nitrosourea derivatives (BCNU, CCNU).

Authors:  G J Hill; R Ruess; R Berris; G W Philpott; P Parkin
Journal:  Ann Surg       Date:  1974-08       Impact factor: 12.969

7.  Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.

Authors:  G A Currie; T J McElwain
Journal:  Br J Cancer       Date:  1975-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.